KRAS and colorectal cancer: Figure 2 shows that the frequency of most gene alterations was similar. However, there were some notorious exceptions on well-known relevant genes for certain cancer types, for example, KRAS and APC in colorectal cancer: 55% and 50% in our cohort vs. 35% and 75% in TCGA, respectively; also, BRCA2 and SMAD4 in pancreatic cancer: 8% and 8% in our cohort vs. 2% and 23% in TCGA; EPHA2 on sarcoma: 11% in our cohort vs. 0%; TP53 and ESR1 in breast cancer: 13% and 13% in our cohort vs. 34% and 0% in TCGA. Other examples were TP53 and ARID1A in ovarian cancer, and TP53 and KRAS in lung cancer.